Tiziana Life Sciences Ltd
NASDAQ:TLSABiotechnology
+$0.03 today
- Market cap
- $103.50M
- Beta
- 0.42
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$0.19
Volume 1.28M
Average 0.21M
TLSA Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Tiziana Life Sciences LtdNASDAQ: TLSA
Other Income / Expenses · Q4 FY2025 · quarter ended Dec 2025
Other income / expenses turns negative
Q4 FY2025 other income / expenses was -$471K, compared with $427K a year earlier.
Context
- Other income / expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 2.85M USD
- Year-over-year change
- +399.7%
- 4-year CAGR
- +31.1%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.85M | +399.7% |
| FY2024 | 2024-12-31 | (952K) | -201.5% |
| FY2023 | 2023-12-31 | 937.89K | +194.1% |
| FY2022 | 2022-12-31 | (996.78K) | -203.1% |
| FY2021 | 2021-12-31 | 967.18K | — |
Other Income / Expenses vs competitors
How TLSA compares with its peers on the latest reported figures
- TLSA's FY2025 other income / expenses of $2.85M is the 4th highest of the 9 companies compared; the peer median is $998.38K.
- Its year-over-year change of +399.7% is the highest of 9, against a peer median of -10.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.47M | +277.4% | — | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $6.9M | -92.4% | +251.1% | — |
| LTM Mar 2026 | $5.99M | -61.1% | -42.7% | — | |
| FY2025 | $2.85M | +399.7% | — | — | |
| LTM Mar 2026 | $1.13M | +25.3% | — | — | |
| LTM Mar 2026 | $869.27K | -45.2% | — | 10.9% | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $374.95K | +127.1% | +1565.2% | — |
| FY2025 | -$781.2K | +29.5% | — | — | |
| LTM Mar 2026 | -$7.37M | -116.5% | — | 4.7% | |
| Peer median (excluding TLSA) | $998.38K | -10.0% | +251.1% | 7.8% | |
Competitors are the stored peer set for TLSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 234K |
| Gross Profit | 0 | 0 | 0 | 0 | (234K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 17.82M | 15.92M | 10.25M | 5.23M | 10.28M |
| Selling, General & Admin | 1.15M | 4.76M | 8.26M | 10.28M | 10.77M |
| Operating Expenses | 36.93M | 17.93M | 22.73M | 15.79M | 21.05M |
| Depreciation & Amortization | 190.2K | 62.68K | 121.34K | 124K | 234K |
| EBITDA | (35.53M) | (18.85M) | (21.66M) | (16.62M) | (21.05M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (36.93M) | (17.93M) | (22.73M) | (15.79M) | (21.28M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 1.46M | 814K | 19K |
| Interest Expense | 237.41K | 8.6K | 12.64K | 6K | 18K |
| Other Income / Expenses | 967.18K | (996.78K) | 937.89K | (952K) | 2.85M |
| Income Before Tax | (35.96M) | (18.92M) | (21.79M) | (16.75M) | (18.43M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (4.37M) | 0 | 567.54K | (4.88M) | 0 |
| Net Income | (31.59M) | (18.92M) | (22.36M) | (11.86M) | (18.43M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.64) | (0.36) | (0.42) | (0.22) | (0.32) |
| EPS (Diluted) | (0.64) | (0.36) | (0.42) | (0.22) | (0.32) |
| Weighted Avg Shares | 48.97M | 50.76M | 50.76M | 53.34M | 59.14M |
| Weighted Avg Shares (Diluted) | 48.97M | 50.76M | 50.76M | 53.34M | 59.14M |
Tiziana Life Sciences Ltd
NASDAQ:TLSA
Intrinsic Alpha fair value
Locked
Current Price
$0.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.